The purpose of the study is to examine disparities in AET adherence and discontinuation among Texas Medicaid-insured early-stage breast cancer patients. Texas Cancer Registry Medicaid-linked database was used from 2000 to 2007 for breast cancer patients aged 20-64. Multivariable logistic regression was performed to test the association of race/ethnicity and geographic factors with AET adherence and discontinuation. Of the 1240 women with breast cancer, 60.8% of non-Hispanic white vs 46.6% of Black patients were adherent to AET in the first year. After adjusting for confounding, Black patients had lower odds of adherence compared to non-Hispanic white patients (Odds ratio 0.62, 95% CI 0.44-0.87), but they were not more likely to discontinue therapy during the study period. Patients from the Texas/Mexico border had higher odds of adherence compared to other regions (OR 2.32, 95% CI 1.29-4.18). There are substantial racial and geographic disparities in AET adherence and discontinuation among Texas Medicaid-insured women.
Introduction
Racial/ethnic disparities in breast cancer mortality have been reported to be attributed to factors such as late stage at diagnosis [1, 2] , socioeconomic status [3] , and the initiation and timing of effective recommended treatment for breast cancer [1, 3] . Timely receipt of nationally recommended treatment leads to substantial reduction in breast cancer mortality [4] and adherence to guidelines for systemic adjuvant endocrine therapy (AET), for example, is associated with improved disease-free survival for women with early-stage breast cancer [5] [6] [7] [8] [9] . It is estimated that treatment with Tamoxifen, a form of AET, can reduce 5-year mortality by up to 26% [5, 7, 10] . Previous studies have examined lower adherence to AET for non-white women, which may contribute to the disparities in breast cancer mortality observed between minorities and white women [11, 12] .
AET treatment includes Tamoxifen and the aromatase inhibitors (AIs, including exemestane, anastrozole, and letrozole). The NCCN recommends that women with early breast cancer receive initial AET with tamoxifen if they are premenopausal at diagnosis or an aromatase inhibitor or tamoxifen if they are postmenopausal. In general, the drugs are typically prescribed every day for 5 years and may involve switching between medications due to complications and/or a change in menopausal status [13] . Understanding adherence and discontinuation during the first 12-months of treatment following breast cancer diagnosis can help identify specific subgroups or those at high risk of non-adherence for further intervention.
Despite the effectiveness of AET to improve survival and decrease cancer recurrence, between 55-75% of breast cancer patients are not adherent to AET during 1-year period [14] and the proportion of being not adherent is even higher for minority women [15, 16] . Previous studies have examined that black patients had 24% lower odds of adherence to AET compared to non-Hispanic white women [11] . Low adherence is associated with the number of other medications prescribed for comorbidities [17] , demographic characteristics such as age [12, 18] , and the side effects [14, [19] [20] [21] [22] [23] . However, little is known about the factors that influence adherence and discontinuation among a group of low-income and racially diverse patients on public insurance. Studies have shown that among the Medicare-insured population, racial/ethnic differences in adherence and discontinuation of AET exist despite comprehensive public insurance; however, they are limited to patients older than 65 years [24] .
Because the known risk factors of adherence to AET, such as low socioeconomic status [11, 16] , and being a minority [11, 16, 24] , are predominately prevalent among the Medicaid population, studying these factors in this population is critical. Texas Medicaid provides comprehensive medical care to breast and cervical cancer patients, and mothers and children in low-income households [25] . The program provides free or low-cost medication to beneficiaries [25] . In Texas, the second most populous state in the U.S., approximately 7% of adults (age 19-64) are Medicaid enrollees [25] . Studies using TCR data have found that black and Hispanic patients diagnosed with breast cancer have a higher risk of mortality [26, 27] which may be due to later stage at diagnosis [27] , low poverty [26, 27] , and residential segregation [28] . No studies have examined AET treatment patterns by race/ethnicity which may further explain the racial/ethnic disparities in mortality. Further, Texans diagnosed with cancer are a population that is widely understudied relative to those in the SEER Cancer registries. Therefore, the objectives of this study are to identify if there are racial/ethnic and sociodemographic differences in (1) 1-year adherence to AET overall, and (2) AET discontinuation during the first year of treatment.
Methods

Database
Texas Cancer Registry (TCR) Medicaid-linked database was used to identify cancer patients from 2000 to 2007. The TCR database contains patient-level demographics, first course of treatment, and other tumor factors, which has been described in detail elsewhere [29] . Medicaid data contain medical claim files for medication use and medical procedures across inpatient, outpatient, and pharmacy settings for patients enrolled in Texas Medicaid.
Study design and population
A total of 1240 women were included in this retrospective cohort study if they were diagnosed with a primary breast cancer at age 20-64 in 2000-2006 who filled a prescription for adjuvant endocrine therapy (AET) within 1 year after diagnosis and were continuously enrolled in Medicaid for 12 consecutive months after the date of AET initiation. Our study only includes women who remained enrolled in Medicaid continuously. Therefore, those that died or who were no longer eligible for enrollment or moved away from Texas during the study period were excluded. Patients were excluded if they had distant stage tumors.
Study outcomes
Adherence of AET was defined by the medication possession ratio (MPR≥80%) for either tamoxifen at initiation or an AI at initiation (yes or no). AIs included anastrozole, exemestane, or letrozole. To calculate the MPR, we analyzed the national drug code (NDC), date of service, and days' supply of medication from Medicaid claims data. MPR was defined as the number of pills supplied over the 1-year period after the initiation of AET. A woman was considered to have initiated AET if the first evidence for a prescription fill for AET was within 12 months of the date of diagnosis. Patients were classified based on their initial AET drug type at initiation. Patients that switched AET medication during the study period were considered to have stopped taking any remaining drug on-hand and to have started the new drug on the first date of prescription fill for the new AET drug. Therefore, any remaining days' supply for the initial drug was not counted in the medication possession ratio.
Discontinuation of AET was defined as a gap in medication supply of ≥ 90 days during the 1 year period after the date of initiation of AET. It was evaluated within several time periods: immediate discontinuation (discontinuation right after the first prescription), discontinuation within 3 months, between 3 and 6 months, and between 6 and 9 months after AET initiation.
Independent variables and covariates
Race/ethnicity was identified from Medicaid and categorized into four groups: White, Black, Hispanic, and Others. Age was grouped into three categories: 20-44, 45-54, or 55-64. Other patient covariates included tumor stage (Local/ Regional), receipt of chemotherapy (Yes/No), radiation therapy (Yes/No), and surgery (Yes/No). Tumor stage was identified through TCR data and included localized tumor as local tumor stage, and those without distant metastasis as regional tumor stage. Treatment with breast cancer surgery, chemotherapy, and radiation therapy was identified from both TCR and Medicaid claims data using procedure codes (ICD-9-CM) and Common Procedure Terminology codes defined elsewhere [30] [31] [32] [33] . A modified version of the Charlson comorbidity index was used to assess the comorbid condition for breast cancer patients [34] [35] [36] . The index is based on the procedure and diagnosis codes (ICD-9-CM) from Medicaid claims record made between 6 months before and 3 months after breast cancer diagnosis. 
Statistical analysis
The distributions of patient demographics and sociodemographic characteristics across the racial/ethnic groups were analyzed first. The χ 2 tests were used to assess whether there were significant differences among race/ethnicity and other variables, and were also used to examine the differences between adherence to AET (any AET at initiation, tamoxifen at initiation, and AI at initiation) and other variables. Three multiple logistic regressions were performed to analyze the relationship between 12-month AET adherence (yes or no) and patient characteristics to examine racial and geographic disparities for each group of patients based on the type of AET they filled a prescription for at initiation (any AET at initiation, tamoxifen at initiation, and AI at initiation). We also examined the association of medication discontinuation yes or no immediately after first prescription, at 3-months, 6-month, and 9-months) with other variables. Multiple collinearity tests were run between each of the independent variables and none were excluded because no variable had a Pearson's correlation coefficient r > 0.7 or a variance inflation factor (VIF) > 7 in the final regression models. All P values are 2-sided and were considered significant at P < 0.05. Statistical analysis was performed using SAS (version 9.4; SAS Institute, Cary, NC).
Results
A total of 1240 Texas Medicaid-insured women with local or regional breast cancer met the selection criteria (Fig. 1 ). Of these, the largest racial/ethnic group was Hispanic which represented 39.4% of the study cohort, followed by non-Hispanic white (38.3%) and black (17.7%) ( Table 1 Of the 1240 patients who were followed for 12 months after the first prescription fill for AET medication (either tamoxifen or an aromatase inhibitor), 733 (59.1%) were adherent (MPR ≥ 80%) ( Table 2 ). A greater proportion of patients that initiated with an AI were adherent compared to those that initiated with tamoxifen (64.3% vs 55.0%). Only 46.6% of black patients were adherent to AET during the study period compared to 60.8% of non-Hispanic white and 61.9% of Hispanic patients.
After controlling for all demographic and treatment characteristics, Black patients compared to non-Hispanic white patients had lower adjusted odds of 1-year adherence (OR 0.62, 95% CI 0.44-0.87) and also had lower odds of adherence if they initiated an AI (OR 0.53, 95% CI 0.32-0.88) ( Table 3) . Hispanics did not have lower odds of AET adherence compared to non-Hispanic white patients. Notably, younger women (aged [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] and those with a comorbidity score of three or more had significantly lower odds of AET adherence compared to women aged 50-64 (OR 0.37, 95% CI 0.20-0.68) and those with 0 comorbidity (OR 0.68, 95% CI 0.48-0.98). Interestingly, Table 3 also shows that women who lived at the Texas-Mexico border had higher odds of AET adherence compared to those who did not (OR 2.32, 95% CI 1.29-4.18). This finding was largely driven by patients who initiated with Tamoxifen in the Texas-Mexico border region (OR 2.84, 95% CI 1.27-6.37). We did not observe differences in AET adherence for women who lived in metropolitan regions compared to those that lived in nonmetro regions (urban or rural), nor did we find an association between poverty level, chemotherapy use, or surgery and adherence to AET in this cohort of Medicaid patients.
Discontinuing AET, or going 90 or more days without AET medication, was not significantly different between black and white patients at any time period (immediately, within 3 months, within 3-6 months, or within 6-9 months) (Table 4) . However, patients aged 20-34 had between 2.4 and 3.4 times higher odds of discontinuing AET treatment immediately to within 6 months of initiating therapy compared to women aged 50-64. Patient who resided within the Texas-Mexico border region had 70% lower odds of discontinuing AET therapy after filling just 1 prescription compared to patients who did not live in the border region of Texas (OR 0.30, 95% CI 0.10-0.87). Surprisingly, Medicaid patients who received radiation therapy had lower odds of discontinuing AET therapy immediately (OR 0.64, 95% CI 0.43-0.95) and within the first three months of treatment (OR 0.63, 95% CI 0.44-0.92) compared to patients who did not.
Discussion
In this racially/ethnically diverse, low-income, Medicaidinsured cohort of women with breast cancer in Texas, we found that black patients had significantly lower odds of adherence to AET compared to white patients, but they were not more likely to discontinue AET therapy anytime within the first 12 months of first prescription. Studies that find a significant racial/ethnic difference in AET adherence are explained by household net worth [11] , or out-of-pocket costs for medications, [24] both of which variables were either controlled for in our study or were not relevant to our population.
A suboptimal proportion of women (59.1%) were adherent to AET medication within the first 12 months after initiating therapy. This is lower than previous reports using similar claims-based methodology among non-elderly privately insured women, which reported 72-81% 12-month adherence to AET [37] [38] [39] [40] [41] . However, unlike our study, they did not include a large proportion of low-income minority women which are factors that are associated with lower likelihood of adherence [11, 16, 17] . Studies using state cancer registry and Medicaid-linked data in North Carolina [17] and New York [42] corroborate our adherence rates and find that adherence ranges from 59 to 60% within the first year of initiation. In the New Jersey Medicaid population, patients who were less indigent than our study found that adherence was slightly higher (70%) [12] . However, these studies did not specifically examine racial/ethnic differences in adherence. The lower rates of adherence could also be driven by age, since almost 40% of our study population was younger than age 50 and younger patients are less likely to be adherent [12, 41] . Alarmingly, black patients were significantly less likely to be adherent to AET compared to non-Hispanic white patients. However, they were not more likely to discontinue treatment. This suggests that while they possessed < 80% of AET medication during the 12-month period, they did not go longer than 90 days without medication. This is an insightful and significant finding because black patients, especially, could benefit from receiving mail-order medication if access to prescriptions is the main driver for having irregular fills. In privately insured populations, the ability to access medication through mail-order pharmacies is associated with better adherence to AET medication [41, 43] . Since having ≥ 80% of medication is associated with the benefits of a reduced risk of breast cancer recurrence and mortality [38, 44] , having less than 80% may indicate that many patients did not receive the full benefits of AET medication, which may contribute to the breast cancer mortality disparity between black and white patients.
We did not observe any differences in AET adherence or discontinuation among patients that lived in Metropolitan vs non-Metro geographic locations. However, we did find that those who lived within the Texas-Mexico border region had higher odds of AET adherence compared to those that did not. This finding may mainly be driven by the high proportion of Hispanics that live in the region. While we studied adherence and discontinuation to AET but not cancer outcomes, this phenomenon might be explained by the Hispanic health paradox whereby Hispanics in the U.S. are less likely to suffer from chronic disease or die prematurely, despite high rates of poverty and less access to education and health care [45] . Philips found that Hispanics with a higher degree of social deprivation were associated with lower mortality among Hispanics in Texas [26] . Hispanics in this border region may have a higher degree of socioeconomic deprivation and may be culturally different (less acculturated) than Hispanics in other regions of Texas which may explain the observation that they have better medication adherence. To the best of our knowledge, this is the first study to find that breast cancer patients living within the Texas-Mexico border have better adherence to AET medication.
This study has several strengths and adds new information to the literature on AET adherence and discontinuation for the Medicaid population. Since Texas Medicaid data were linked with the Texas Cancer Registry data, we were able to assess the date of cancer diagnosis more accurately which allowed us to study AET adherence and discontinuation during the first year of initiating therapy. Next, we included baseline demographic and clinical characteristics which may have confounded the observed associations with adherence because prior reports on AET adherence strictly rely on medical claims data [39, 46] .
Our study was limited first, by the population, which included only women < 65 years enrolled in Medicaid.
Therefore, results may not be generalizable to older patients or those with private insurance which may have copayments or out-of-pocket costs for medications. Second, we did not have patient-reported measures for non-adherence and there could be unmeasured confounding factors affecting the validity of the study findings. Psychosocial factors related to the quality of care that women receive such as physician-patient communication, for example, may influence women's AET adherence but could not be captured in this study [47, 48] , or the adverse effects of the medication [49] . Third, calculating adherence using Medicaid prescription claims assumes that patients take the medications as often as they refill prescriptions. Some patients might have refilled AET medication but did not take it. Nevertheless, pharmacy records are considered as the most objective and accurate estimation of actual medication use in large populations over time [50, 51] . Finally, we only examined adherence and discontinuation within a 12-month period from the date of initiation; however, this may be the most critical period to study adherence, since non-adherence in subsequent years is low [37] .
Conclusions
There were substantial racial and geographic disparities in AET adherence and discontinuation among Texas Medicaid-insured women with breast cancer. In these racially diverse Texas Medicaid-insured breast cancer patients, black patients were less likely to be adherent to AET treatment within 12 months of initiating therapy compared to nonHispanic white patients. This was especially true for black patients that initiated AET with an AI but not among those that initiated with tamoxifen. However, they were not less likely to discontinue therapy. Future research should examine whether racial/ethnic differences in adherence to AET is associated with mortality. Still, expanding the access to prescription medication, such as mail-in pharmacy orders in Medicaid, could improve treatment adherence.
